About the drug – For specialists

For specialists

 

The world’s first injectable drug based on pure chondroitin sulphate

Story

 

1986 - 198819881989199219942002201520162018
THE PRODUCTION TECHNOLOGY OF CHONDROITIN SULFATE OF SUBSTANCE (WORKING TITLE ARTRON) IS DEVELOPED AND IMPLEMENTED
REPLACE WORK TITLE ARTHRON SET NAME MUKOSAT
RESEARCH 1 AND 2 PHASES WAS PERFORMED
BY RESULTS OF 3 PHASES OF CLINICAL STUDY, A PERMISSION FOR INDUSTRIAL ISSUE OF THE DRUG OF MUKOSAT IN THE MEDICINAL FORM Was Obtained – 10% SOLUTION IN AMPULES ON 1 AND 2 ML.
THE INSTRUCTION FOR MUKOSAT Was APPROVED BY The PHARMACOLOGICAL COMMITTEE Of The Ministry Of Health Of The Russian Federation (REG No. 94/81/16)

PATENT No. 2021812 RECEIVED FOR “MEANS FOR TREATMENT OF ARTHROLOGICAL DISEASES” FOR “MUKOSAT”

Mucosat® TRADEMARK REGISTERED
PATENT No. 2580589 “METHOD FOR PREPARING THE INJECTION FORM OF THE PRODUCT OF CHONDROITIN SULPHATE” IS RECEIVED. PRIORITY DATE: 01/27/2015

PATENT No. 2612019 “METHOD FOR PRODUCING INJECTION FORM OF THE DRUG BASED ON CHONDROITIN SULPHATE” IS RECEIVED. PRIORITY DATE: 12/11/2015

PATENT No. 2612014 “MEANS FOR TREATMENT OF ARTHROLOGICAL DISEASES” IS RECEIVED. PRIORITY DATE: 10/19/2015

A CERTIFICATE IS RECEIVED FOR TK “MUKOSAT” No. 2612014 DATE OF REGISTRATION OF THE AGREEMENT OF REMOVAL OF RIGHTS FROM “GILSINP” IN FAVOR OF LLC “DIAMED-PHARMA”: 05.10.2015

CERTIFICATE IS RE

CERTIFICATE IS RECEIVED FOR TK “MUCOSAT” TK: No. 614977 DATE OF PRIORITY: 05/30/2016

CHANGE OF REGISTRATION CERTIFICATE HOLDER P N000570 / 01 IN FAVOR OF DIAMED-PHARMA LLC

A NEW REGISTRATION CERTIFICATE IS RECEIVED: P N000570 / 01 OF 04/09/2018.
Mucosat® – Original and reference chondroprotector with patented production technology Features of the drug

Features of the drug

 

  • ORIGINAL DEVELOPMENT
  • PATENTED MANUFACTURING TECHNOLOGY
  • HIGH SAFETY PROFILE
    DUE TO THE ABSENCE OF TOXIC EXCIPIENTS

Instructions for use

 

REDUCES INFLAMMATION AND PAIN
PREVENTS CARTILAGE DESTRUCTION
REDUCES STIFFNESS AND IMPROVES JOINT MOBILITY
NORMALIZES CARTILAGE TISSUE REPAIR PROCESSES

RELEASE FORM

 

AMPOULES WITH A SOLUTION FOR V / M ADMINISTRATION OF 1 ML OR 2 ML (100 MG / ML)

INDICATIONS FOR USE

 

DEGENERATIVE DISEASES OF THE JOINTS AND SPINE:

  • OSTEOARTHROSIS OF THE SPINE
  • OSTEOARTHROSIS OF THE SPINE

DOSAGE AND ADMINISTRATION

 

1 ml First 3 injections, every other day
2 ml C 4 injections until the end of the course, every other day
25-30 injection Recommended course of therapy
after 6 months If necessary, repetition is possible